Teva Pharmaceutical Industries Limited (NYSE:TEVA) closed its last session at $50.89 with the change of +0.73%. The market capitalization of the company is $46.51B with an average Volume of 6.08 million shares. The stock currently has its 52-Week High range of $72.31 and 52-week low range of $48.01. The Price to Book (P/B) ratio stands at 1.72. The stock traded total quantity of 4.85 million shares.
For the current Fiscal Quarter, 21 analysts have given an average earnings per share forecast of $1.17. The Low Earnings per share estimate of the current Quarter is $1.02 and High Estimate is set at $1.22 according to these Analysts opinions. The Previous Year EPS of this Quarter is $1.43.
According to 20 analysts, an average sales Estimate of the current Fiscal quarter is $4.81B. The lower sales estimate is $4.65B and higher sales estimate is $4.96B according to these Analysts thoughts.
The Company currently has Highest Price Target of $100 and Lowest Price Target of $58. It has Median Price Targets of $73. Mean price target is set at $71.68 after consensus analysis of 22 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 0 analysts have assigned this stock as Strong Buy where 10 assigned Buy, 11 analysts believe it’s a Hold, 5 said Underperform and 0 assigned Sell rating.
Endologix, Inc. (NASDAQ:ELGX) ended its last trade at $14.24 with the move of +3.94%. The company has market value of $1.17B with the total traded volume of 1.31 million. The stock currently has its 52-Week top value of $15.53 and 52-week down value of $6.51. The price to book (P/B) ratio of the company is 8.28. Its previous closing price was recorded at $13.70.
For the current Fiscal Quarter, 10 analysts have given an Average earnings estimate of $-0.2 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-0.26 while High Estimate is $-0.15. The Previous Year EPS of this Quarter is $-0.18.
According to 10 analysts, an Average Revenue Estimate of the current Fiscal quarter is $46.42M. According to them, the Low Revenue estimate is $45.10M and High Revenue estimate is $49.20M.
The Company currently has High Price Target of $17. The Low and Mean Price Targets are $13 and $15.41 respectively. These price targets are set after consensus analysis of 11 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 0 analysts have given this stock as Strong Buy where 6 issued Buy, 4 analysts think that it’s a Hold, 1 told Underperform and0 assigned Sell rating.